H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Foamix Pharma (FOMX) today and set a price target of $12. The company’s shares closed yesterday at $3.86, close to its 52-week low of $3.21.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -21.7% and a 16.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Foamix Pharma is a Strong Buy with an average price target of $17.
See today’s analyst top recommended stocks >>
Based on Foamix Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.48 million. In comparison, last year the company had a GAAP net loss of $17.36 million.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.
